ARPO
Income statement / Annual
Last year (2022), Aerpio Pharmaceuticals, Inc.'s total revenue was $5.51 M,
an increase of 23.11% from the previous year.
In 2022, Aerpio Pharmaceuticals, Inc.'s net income was -$36.92 M.
See Aerpio Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
Operating Revenue |
$5.51 M |
$4.47 M |
$823,000.00 |
$0.00 |
$0.00 |
$0.00 |
Cost of Revenue |
$35.02 M
|
$20.02 M
|
$14.44 M
|
$8.32 M
|
$0.00
|
$0.00
|
Gross Profit |
-$29.51 M
|
-$15.54 M
|
-$13.62 M
|
-$8.32 M
|
$0.00
|
$0.00
|
Gross Profit Ratio |
-5.36
|
-3.47
|
-16.55
|
0
|
0
|
0
|
Research and Development Expenses |
$35.02 M
|
$20.02 M
|
$14.44 M
|
$9.82 M
|
$15.14 M
|
$12.75 M
|
General & Administrative Expenses |
$7.44 M
|
$8.28 M
|
$7.97 M
|
$8.16 M
|
$2.52 M
|
$2.71 M
|
Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$1.50 M
|
$1.40 M
|
$1.37 M
|
Selling, General & Administrative Expenses |
$7.44 M
|
$8.28 M
|
$7.97 M
|
$9.67 M
|
$3.92 M
|
$4.08 M
|
Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Operating Expenses |
$7.44 M
|
$7.56 M
|
$7.96 M
|
$10.32 M
|
$15.93 M
|
$15.33 M
|
Cost And Expenses |
$42.45 M
|
$27.57 M
|
$22.40 M
|
$18.64 M
|
$15.93 M
|
$15.33 M
|
Interest Income |
$29,000.00
|
$59,000.00
|
$600,000.00
|
$835,000.00
|
$768,000.00
|
$202,000.00
|
Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Depreciation & Amortization |
$892,000.00
|
$1.17 M
|
$1.11 M
|
$1.35 M
|
$1.35 M
|
$1.53 M
|
EBITDA |
-$36.05 M |
-$22.65 M |
-$20.47 M |
-$16.64 M |
-$9.54 M |
-$13.92 M |
EBITDA Ratio |
-6.55
|
-5.06
|
-24.88
|
0
|
0
|
0
|
Operating Income Ratio |
-6.71
|
-5.32
|
-26.23
|
0
|
0
|
0
|
Total Other Income/Expenses Net |
$29,000.00
|
$667,000.00
|
-$594,000.00
|
-$1.49 M
|
-$5.81 M
|
$330,000.00
|
Income Before Tax |
-$36.92 M
|
-$23.16 M
|
-$22.18 M
|
-$19.48 M
|
-$16.70 M
|
-$15.13 M
|
Income Before Tax Ratio |
-6.7
|
-5.18
|
-26.95
|
0
|
0
|
0
|
Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Net Income |
-$36.92 M
|
-$23.16 M
|
-$22.18 M
|
-$19.48 M
|
-$16.70 M
|
-$15.13 M
|
Net Income Ratio |
-6.7
|
-5.18
|
-26.95
|
0
|
0
|
0
|
EPS |
-1.08 |
-0.96 |
-1.35 |
-2.43 |
-3.59 |
-2.25 |
EPS Diluted |
-1.08 |
-0.96 |
-1.35 |
-2.43 |
-3.59 |
-2.25 |
Weighted Average Shares Out |
$34.29 M
|
$24.10 M
|
$16.42 M
|
$7.64 M
|
$4.65 M
|
$6.74 M
|
Weighted Average Shares Out Diluted |
$34.29 M
|
$24.10 M
|
$16.42 M
|
$8.01 M
|
$4.65 M
|
$6.74 M
|
Link |
|
|
|
|
|
|